Gulf Coast TX
Syndax says mid-stage trial of lung disease treatment fails main goal, ends development
Oct 12 (Reuters) -- Syndax Pharmaceuticals said on Monday it will stop developing a treatment for idiopathic pulmonary fibrosis, a chronic lung-scarring disease, after a mid-stage…
